Innate Lymphoid Cells and Intestinal Inflammatory Disorders

Int J Mol Sci. 2022 Feb 6;23(3):1856. doi: 10.3390/ijms23031856.

Abstract

Innate lymphoid cells (ILCs) are a population of lymphoid cells that do not express T cell or B cell antigen-specific receptors. They are largely tissue-resident and enriched at mucosal sites to play a protective role against pathogens. ILCs mimic the functions of CD4 T helper (Th) subsets. Type 1 innate lymphoid cells (ILC1s) are defined by the expression of signature cytokine IFN-γ and the master transcription factor T-bet, involving in the type 1 immune response; ILC2s are characterized by the expression of signature cytokine IL-5/IL-13 and the master transcription factor GATA3, participating in the type 2 immune response; ILC3s are RORγt-expressing cells and are capable of producing IL-22 and IL-17 to maintain intestinal homeostasis. The discovery and investigation of ILCs over the past decades extends our knowledge beyond classical adaptive and innate immunology. In this review, we will focus on the roles of ILCs in intestinal inflammation and related disorders.

Keywords: ILC1; ILC2; ILC3; intestinal inflammation.

Publication types

  • Review

MeSH terms

  • Animals
  • Gastroenteritis / immunology*
  • Gene Expression Regulation
  • Humans
  • Immunity, Innate
  • Interferon-gamma / metabolism
  • Interleukin-17 / metabolism
  • Interleukin-22
  • Interleukins / metabolism
  • Lymphocytes / immunology*
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism
  • T-Box Domain Proteins / metabolism

Substances

  • IFNG protein, human
  • Interleukin-17
  • Interleukins
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • RORC protein, human
  • T-Box Domain Proteins
  • T-box transcription factor TBX21
  • Interferon-gamma